Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations

Histopathology

Volumn 57, Issue 6, 2010, Pages 877-884

  Pristauz, Gunda ^a   Petru, Edgar ^a   Stacher, Elvira ^a   Geigl, Jochen B ^b   Schwarzbraun, Thomas ^b   Tsybrovskyy, Oleksiy ^a   Winter, Raimund ^a   Moinfar, Farid ^a  

^a Department of Obstetrics and Gynecology ^*  (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Androgen receptor; BRCA1; BRCA2; Breast cancer; Steroid receptors

Indexed keywords

ANDROGEN RECEPTOR; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA; CLUSTER ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 78650248649     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03724.x     Document Type: Article

References (30)

1. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 2001; 10; 705-713.
2. Scully R, Livingston DM. In search of the tumour- suppressor functions of BRCA1 and BRCA2. Nature 2000; 408; 429-432.
3. Wooster R, Weber BL. Genomic medicine: breast and ovarian cancer. N. Engl. J. Med. 2003; 348; 2339-2347.
4. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1- mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343; 692-695.
5. Ford D, Easton DF, Stratton M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1998; 62; 676-689.
6. Antoniou A, Pharoah PDP, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 2003; 72; 1117-1130.
7. Musolino A, Bella MA, Bortesi B et al. BRCA mutations, molecular markers, and clinical variables in early- onset breast cancer: a population- based study. Breast 2007; 16; 280-292.
8. Li WF, Hu Z, Rao NY et al. The prevalence of BRCA1 and BRCA2 germline mutations in high- risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res. Treat. 2008; 110; 99-109.
9. Moinfar F, Okcu M, Tsybrovskyy O et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003; 98; 703-711.
10. Hall RE, Aspinall JO, Horsfall DJ et al. Expression of the androgen receptor and an androgen- responsive protein, apolipoprotein D, in human breast cancer. Br. J. Cancer 1996; 74; 1175-1180.
11. Kuenen- Boumeester V, Van der Kwast TH, Claassen CC et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur. J. Cancer 1996; 32A; 1560-1565.
12. Castellano I, Allia E, Accortanzo V et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res. Treat. 2010; 124; 607-617.
13. Berns EM, Dirkzwager- Kiel MJ, Kuenen- Boumeester V et al. Androgen pathway dysregulation in BRCA1- mutated breast tumors. Breast Cancer Res. Treat. 2003; 79; 121-127.
14. Meindl A; German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int. J. Cancer 2002; 97; 472-480.
15. Engert S, Wappenschmidt B, Betz B et al. MLPA Screening in the BRCA1 gene from 1, 506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early- onset cases. Hum. Mutat. 2008; 29; 948-958.
16. Tavassoli FA. Pathology of the breast. Stamford, CT: Appleton & Lange, 1998.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long- term follow- up. Histopathology 1991; 19; 403-410.
18. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 2009; 20; 1319-1329.
19. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
20. Norušis MJ; SPSS Inc. SPSS professional statistics, version 6.1. Chicago, IL: SPSS, Inc., 1994; 267-277.
21. Secreto G, Zumoff B. Abnormal production of androgens in women with breast cancer. Anticancer Res. 1994; 14; 2113-2118.
22. Secreto G, Toniolo P, Berrino F et al. Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer Res. 1991; 51; 2572-2576.
23. Adams JB. Adrenal androgens and human breast cancer: a new appraisal. Breast Cancer Res. Treat. 1998; 51; 183-188.
24. Wang DY, Allen DS, Stavola BD et al. Urinary androgens and breast cancer risk: results from a long- term prospective study based in Guernsey. Br. J. Cancer 2000; 82; 1577-1584.
25. Giguere Y, Dewailly E, Brisson J et al. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in general population. Cancer Res. 2001; 61; 5869-5874.
26. Rebbeck TR, Kantoff PW, Krithivas K et al. Modification of BRCA1- associated breast cancer risk by the polymorphic androgen- receptor CAG repeat. Am. J. Hum. Genet. 1999; 64; 1371-1377.
27. Honma N, Takubo K, Sawabe M et al. Estrogen- metabolizing enzymes in breast cancers from women over the age of 80 years. J. Clin. Endocrinol. Metab. 2006; 91; 607-613.
28. Zeleniuch- Jacquotte A, Gu Y, Shore RE et al. Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. Int. J. Cancer 2005; 114; 323-327.
29. Fan S, Wang J- A, Yuan R et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999; 284; 1354-1356.
30. Park JJ, Irvine RA, Buchanan G et al. Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor. Cancer Res. 2000; 60; 5946-5949.